Eli Lilly Halts India Obesity Campaign Amid Regulator Probe

Eli Lilly has paused its "We Know Now" obesity awareness campaign in India after the country's drug regulator issued a warning. The regulator stated the campaign may break rules against indirectly advertising prescription drugs. The company is seeking clearer guidance on India's strict promotional rules, which differ significantly from U.S. practices.

Campaign Paused Over Ad Rule Concerns

Eli Lilly's "We Know Now" campaign aimed to highlight obesity as a chronic disease. However, India's Drugs Controller General warned that the campaign, which included newspaper ads, social media, and celebrity endorsements, could violate rules prohibiting the indirect promotion of prescription medicines. The company stated it paused the initiative out of "regulatory caution," citing "significant regulatory uncertainty." Eli Lilly noted that guidance received seemed to restrict even non-branded, doctor-led awareness campaigns, a stance it found difficult to reconcile with suggestions for public health initiatives. This lack of clear rules could prevent important public health messages. In contrast, the U.S. Food and Drug Administration (FDA) permits direct-to-consumer advertising of prescription drugs, a practice strictly forbidden in India under laws like the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

India's Growing Obesity Market Faces Competition

The Indian market for obesity and diabetes treatments is expanding rapidly, with projections estimating it could reach ₹80 billion (about $839 million) annually by 2030. Eli Lilly's GLP-1 treatment, Mounjaro, launched in India in March 2025, quickly became the country's top-selling drug by value. However, it faces strong competition from Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy. In April 2026, Novo Nordisk saw sales jump 40% after significant price cuts, bringing its drugs to around 5,660 rupees ($60) to combat generic alternatives. By March 2026, generic semaglutide products from 13 manufacturers entered the market, reducing Eli Lilly's GLP-1 market share from 61% to 56%. Despite this, Mounjaro remained India's top GLP-1 provider by value and was the number one drug in the Indian pharmaceutical market in April 2026.

Regulatory Hurdles and Market Pressures

The regulator's warning poses a real risk to Eli Lilly's market strategy in India. The country's laws strictly prohibit public advertising of prescription drugs, including indirect promotions that build brand awareness. The "We Know Now" campaign, even without naming Mounjaro, may have attracted regulatory attention by increasing product visibility, especially given its timing after Mounjaro's launch. This regulatory challenge could lead to penalties and require substantial changes to marketing strategies. India's framework emphasizes physician-led consultations, creating a significant hurdle for broad consumer campaigns. The market is also very price-sensitive, as shown by Novo Nordisk's aggressive price cuts against generics. Eli Lilly's premium pricing for Mounjaro could face further pressure as generic options grow.

Market Outlook and Investor View

Analysts expect strong growth in the global obesity drug market, projected to hit $150 billion annually by 2030. Eli Lilly's current P/E ratio of about 34.1x suggests investor confidence in its future earnings, trading at a valuation lower than the market's average P/E of around 38.43. The company currently holds a consensus 'Moderate Buy' rating with an average price target near $1,218.33. However, Eli Lilly faces ongoing challenges, including regulatory friction in India, intense competition from Novo Nordisk, and the rise of generic drugs. Adapting its marketing approach to comply with India's advertising rules while maintaining market leadership will be key to its future success in this important area.